Skye Bioscience, Inc.

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing new molecules that interact with G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic disorders. The company's main product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody that targets cannabinoid receptor 1 (CB1), a GPCR involved in metabolic regulation. Skye aims to advance nimacimab through clinical development for obesity and overweight, both as a combination therapy and potentially as a standalone or second-line treatment. They also plan to explore nimacimab's use in other metabolic indications where inflammation and fibrosis play a role, and to evaluate it in combination with incretin-based therapies. Skye seeks strategic partnerships and business development opportunities to accelerate nimacimab's development and is also developing next-generation GPCR-targeting molecules. The company acquired nimacimab through the acquisition of Bird Rock Bio, Inc. in August 2023. Nimacimab is a humanized IgG4 negative allosteric modulating (NAM) antibody that specifically binds to the CB1 receptor without cross-reactivity to other GPCRs, including cannabinoid receptor 2 (CB2).